Literature DB >> 6609035

In vitro hyporeactivity to alpha-interferon in children with severe combined immunodeficiency disease.

B R Williams, S E Read, E W Gelfand.   

Abstract

Interferon (IFN) treatment of peripheral blood mononuclear cells from seven children with severe combined immunodeficiency (SCID) failed, with one exception, to induce the IFN-dependent enzyme, 2-5A synthetase or enhance natural killer cell activity. In one patient this hyporeactivity was demonstrated in both T cell enriched and T cell depleted lymphocyte preparations. These results may reflect the absence of an IFN reactive lymphocyte subpopulation or of the IFN receptor. This defect in SCID patients may be partly responsible for their increased susceptibility to viral infections and may contribute to the regulatory imbalances in T lymphocyte subpopulations.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6609035      PMCID: PMC1535959     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  5 in total

1.  Induction and separation of antigen-dependent T helper and T suppressor cells in man.

Authors:  A Shore; H Dosch; E W Gelfand
Journal:  Nature       Date:  1978-08-10       Impact factor: 49.962

2.  Activation of a suppressor T-cell pathway by interferon.

Authors:  T M Aune; C W Pierce
Journal:  Proc Natl Acad Sci U S A       Date:  1982-06       Impact factor: 11.205

3.  Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases.

Authors:  A Schattner; D Wallach; G Merlin; T Hahn; S Levin; M Revel
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

4.  Significance of viral infections in severe combined immunodeficiency disease.

Authors:  W R Jarvis; P J Middleton; E W Gelfand
Journal:  Pediatr Infect Dis       Date:  1983 May-Jun

5.  Serum interferon in Navajo children with severe combined immunodeficiency disease inhibits lymphoblastogenesis.

Authors:  J F Jones; L M Minnich; D O Lucas; V A Fulginiti; Z Ingham; M P Langford; G J Stanton
Journal:  J Clin Immunol       Date:  1983-01       Impact factor: 8.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.